COMPOSITION COMPRISING RECOMBINANT GpIba RECEPTOR PROTEIN
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application PCT/IB2019/051227, filed Feb 15, 2019. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,746,140 | COMPOSITION COMPRISING RECOMBINANT GpIba RECEPTOR PROTEIN In force · High confidence | F. Hoffmann-La Roche AG | In force | High confidence | ||
| US 12,509,500 | Composition Comprising Recombinant Gpiba Receptor Protein In force · High confidence | F. Hoffmann-La Roche AG | In force | High confidence |
2 of 2 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.